International Journal of Radiation Research

en Expression of regulatory T cells in driver-gene-negative advanced non-small cell lung cancer as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;">Background: The To measure regulatory T cells (Tregs) expression in driver-gene-negative advanced non-small cell lung cancer (NSCLC) as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors (ICIs). Materials and Methods: Fifty patients with advanced non-small cell lung cancer without driving genes who were receiving treatment with a monoclonal antibody targeting the programmed death receptor-1 (PD-1) made up the study group. 30 healthy subjects in the same period were chosen into the control group. Flow cytometry was used to identify CD4highCD25+Foxp3+Treg cells in peripheral blood of all participants. Relation between CD4highCD25+Foxp3+Treg cells and tumor markers were explored, and efficacy and prognosis in patients before and after therapy was analyzed. Results: The fraction of CD4highCD25+Foxp3+Treg cells in the study group was higher (P<0.05). Following three rounds of PD-1 monoclonal antibody treatment, patients' CD4highCD25+Foxp3+Treg cells proportion was lower than before treatment (P<0.01), and showed a positive correlation with tumor markers (P<0.05). The fraction of CD4highCD25+Foxp3+Treg cells in the CR+PR group decreased in both the second and third cycles after treatment compared to the SD+PD group (P<0.01), but no change was found before or during the first cycle (P>0.05). CD4highCD25+Foxp3+Treg cells proportion in the death group presented higher relative to the survival group (P<0.05). CD4highCD25+Foxp3+Treg cells predicted the area under the ROC curve was 0.8134, with significant difference (P<0.05). Conclusion: CD4highCD25+Foxp3+Treg cells proportion in peripheral blood of NSCLC patients shows increased, and has predictive value for therapeutic efficacy of ICIs and prognosis of driver-gene-negative advanced NSCLC patients.</div> Non-small cell lung cancer, regulatory T cells, immune checkpoint inhibitors, prognosis. 455 461 http://ijrr.com/browse.php?a_code=A-10-1-1194&slc_lang=en&sid=1 Y. Chen 13990829946@163.com 7900319475328460027856 7900319475328460027856 Yes Department of Respiratory and Critical Care Medicine, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan 637000, China S. Chen 7900319475328460027857 7900319475328460027857 No Department of Oncology, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan 637000, China Y. Li 7900319475328460027858 7900319475328460027858 No Department of Respiratory and Critical Care Medicine, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan 637000, China X. Guo 7900319475328460027859 7900319475328460027859 No Department of Pathology, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan 637000, China Q. Liang 7900319475328460027860 7900319475328460027860 No Department of Thoracic Surgery, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan 637000, China L. Yang 7900319475328460027861 7900319475328460027861 No Department of Respiratory and Critical Care Medicine, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan 637000, China C. Lei 7900319475328460027862 7900319475328460027862 No Department of Respiratory and Critical Care Medicine, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan 637000, China